Arcus biosciences to present preliminary data from phase 1 portion of arc-8 study for ab680 in metastatic pancreatic cancer at asco-gi symposium

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary data from the ongoing dose-escalation portion of its arc-8 phase 1/1b study, evaluating the safety and tolerability of ab680, the first small-molecule cd73 inhibitor to enter the clinic, in combination with zimberelimab (anti-pd-1) and nab-paclitaxel plus gemcitabine (chemotherapy) in front-line me
RCUS Ratings Summary
RCUS Quant Ranking